Pure Global

Effect of Postbiotic Product on Colonic Barriers in IBS - Trial NCT05475314

Access comprehensive clinical trial information for NCT05475314 through Pure Global AI's free database. This phase not specified trial is sponsored by Nordisk Rebalance A/S and is currently Completed. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05475314
Completed
dietary supplement
Trial Details
ClinicalTrials.gov • NCT05475314
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effect of Postbiotic Product on Colonic Barriers in IBS
A Postbiotic Fermented Oat Gruel May Have a Beneficial Effect on the Colonic Mucosal Barrier in Patients With Irritable Bowel Syndrome

Study Focus

ReFerm(R)

Interventional

dietary supplement

Sponsor & Location

Nordisk Rebalance A/S

Linköping, Sweden

Timeline & Enrollment

N/A

Dec 01, 2020

Apr 30, 2022

30 participants

Primary Outcome

Intestinal permeability

Summary

Impaired intestinal permeability and microbial dysbiosis are important pathophysiological
 mechanisms underlying irritable bowel syndrome (IBS). ReFerm®, also called Profermin®, is a
 postbiotic product of oat gruel fermented with Lactobacillus plantarum 299v. In this
 experimental study, we investigated whether ReFerm® has a beneficial effect on the intestinal
 epithelial barrier function in patients with IBS.

ICD-10 Classifications

Irritable bowel syndrome with predominant constipation [IBS-C]
Irritable bowel syndrome
Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Irritable bowel syndrome with mixed bowel habits [IBS-M]
Other and unspecified irritable bowel syndrome

Data Source

ClinicalTrials.gov

NCT05475314

Non-Device Trial